ArticleEuropean journal of pediatrics2026
The PVL threat: A multicenter, single-cohort retrospective study of Panton-Valentine leukocidin staphylococcal infections in critically ill children.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus carrying the Panton-Valentine leukocidin (PVL) genes, in both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains, causes severe infection in previously healthy children. We described critically ill children with PVL-positive infection and explored predictors of prolonged intensive care. In this multicenter, single-cohort retrospective study, we included 44 consecutive children aged 0-16 years with PVL-producing S. aureus infection admitted to a neonatal or pediatric intensive care unit (PICU) at 13 Italian centers between 2022 and 2025. The primary outcome was PICU stay above the cohort median. We used Fisher exact tests and exploratory Firth penalized logistic regression, overall and within age strata, with sensitivity analyses. Median age was 22 months (interquartile range [IQR] 11-123); 5 children (11%) were neonates. MSSA caused 25 cases (57%) and MRSA 19 (43%). Necrotizing pneumonia predominated, with excavation in 34 children (77%). Empyema (52%), acute respiratory distress syndrome (41%), pneumothorax (36%) and septic shock (34%) were the leading complications; 41 children (93%) required respiratory support and 4 (9%) extracorporeal membrane oxygenation. Median PICU stay was 17 days (IQR 10-28); 2 children died (5%). Septic shock was associated with prolonged stay (odds ratio 7.2; 95% CI 1.5-49.3), also after adjustment in children ≥ 1 year (adjusted odds ratio 8.0; 95% CI 1.3-49.8), with consistent but imprecise sensitivity analyses.
conclusionPVL-producing S. aureus caused life-threatening infection at all pediatric ages. Methicillin resistance was not associated with prolonged stay, supporting PVL testing of S. aureus isolates from critically ill children. Predictors of prolonged stay are exploratory and need prospective confirmation. WHAT IS KNOWN: • PVL-producing S. aureus causes necrotizing pneumonia and disseminated infection in previously healthy children. • Evidence rests largely on case reports and small series, and infants are underrepresented. WHAT IS NEW: • In 44 critically ill children, including 5 neonates, MSSA and MRSA produced comparable critical illness. • In exploratory analyses, septic shock was associated with prolonged intensive care; mortality was 5%.
Indexed as
Identifiers
42873304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.